Brooklyn Investment Group Purchases New Position in Natera, Inc. (NASDAQ:NTRA)

Brooklyn Investment Group bought a new position in Natera, Inc. (NASDAQ:NTRA) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 553 shares of the medical research company’s stock, valued at approximately $70,000.

A number of other large investors have also added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. purchased a new stake in shares of Natera in the 2nd quarter worth $28,000. Quarry LP lifted its holdings in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. GAMMA Investing LLC raised its position in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the period. Covestor Ltd raised its position in Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Finally, Tobam purchased a new stake in Natera in the 2nd quarter worth about $74,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Up 0.1 %

Shares of NASDAQ NTRA opened at $168.45 on Friday. Natera, Inc. has a 12-month low of $53.88 and a 12-month high of $171.95. The company has a market cap of $22.24 billion, a P/E ratio of -95.71 and a beta of 1.53. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average price of $133.88 and a 200 day moving average price of $119.43.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the prior year, the firm earned ($0.95) EPS. The firm’s quarterly revenue was up 63.9% compared to the same quarter last year. Research analysts anticipate that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Insider Activity at Natera

In other Natera news, Director Gail Boxer Marcus sold 2,212 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the transaction, the director now directly owns 19,386 shares of the company’s stock, valued at $3,073,262.58. This represents a 10.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rowan E. Chapman sold 2,614 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $127.68, for a total transaction of $333,755.52. Following the completion of the transaction, the director now directly owns 7,969 shares of the company’s stock, valued at approximately $1,017,481.92. The trade was a 24.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 46,503 shares of company stock worth $6,325,804. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NTRA. UBS Group reduced their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Sanford C. Bernstein raised their target price on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Stephens reiterated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. Canaccord Genuity Group raised their target price on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $140.59.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.